Andrx’ Declining Revenue Reflects Cost Of Investments
This article was originally published in The Pink Sheet Daily
The company says its decline in total revenues is reflective of its continued development of manufacturing processes and facilities.
You may also be interested in...
FDA will continue to block approval of Andrx' oral contraceptives until manufacturing issues are resolved despite the company's intention to transfer its pending ANDAs to Teva
The company has been placed in “Official Action Indicated” status following an FDA inspection that resulted in a “Form 483.”
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue